Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

NCT02437487 is registered in ClinicalTrials.gov with Seres Therapeutics, Inc. as lead sponsor.

NCT NCT02437487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection
Lead sponsor
Seres Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2016
Enrollment
89 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile